LEQEMBI Moves Beyond the Infusion Center: A New At-Home Option for Alzheimer’s Treatment

For the past several years, LEQEMBI® (lecanemab) has represented an important shift in societies treatment of Alzheimer’s disease. This drug has stood as a first-of-its kind, targeting amyloid pathology which is believed to contribute to the progression of Alzheimer’s disease. It has become one of the first treatments shown to minimally slow the progression of early Alzheimer’s disease. Now, after about three years on the market, treatment methodology for LEQEMBI is changing, eliminating the need for administration at an infusion center.

In July 2026, the U.S. Food and Drug Administration (FDA) approved a new subcutaneous formulation of LEQEMBI, called LEQEMBI IQLIK, which can be administered at home using an autoinjector by the patient or a caregiver. This approval means that eligible patients can now begin treatment with the at-home injection rather than starting with intravenous (IV) infusions.

The change will help to reduce the logistical burden associated with anti-amyloid treatment. Instead of traveling to an infusion center every two weeks, patients and/or their caregivers may be able to administer the medication at home on a weekly basis. Reports have shown that the autoinjector was found easy to use by 94% of patients and caregivers that participated in an acceptability study. Additionally, recent data presented at the Alzheimer’s Association International Conference (AAIC) 2026 found that the subcutaneous formulation produced clinical efficacy, amyloid removal, and safety outcomes comparable to the IV regimen.

Important Limitations to Consider

While moving LEQEMBI treatment from the infusion center to the home is certainly a step in the right direction, it does not address the significant limitations of the treatment itself:

• Limited to early Alzheimer’s disease:LEQEMBI is approved for people with mild cognitive impairment or early-stage Alzheimer’s disease. It is not approved for other forms of dementia or for later stages of Alzheimer’s disease.
• Requires ongoing monitoring and carries the risk of serious side effects:Treatment carries a risk of amyloid-related imaging abnormalities (ARIA), which can include brain swelling (ARIA-E) and small areas of bleeding in the brain (ARIA-H). Patients require medical evaluation and periodic MRI monitoring before and during treatment.
• At-home administration does not eliminate medical oversight:While the new formulation can be administered at home, patients still require ongoing medical supervision, including appropriate testing and monitoring.
• Cost and access remain barriers:The medication itself costs roughly $30,000 annually per patient, before additional costs associated with infusions, imaging, clinical visits, and other care. Medicare coverage is available only to eligible patients who meet specified requirements.
• Slows but does not stop or reverse disease progression:LEQEMBI has been shown to slow cognitive and functional decline in people with early Alzheimer’s disease, but it does not cure Alzheimer’s, restore lost abilities, or stop the underlying disease from progressing.

For CTF, this is precisely why continued investment in innovative, translational dementia research is so critical. We need new treatments that can work earlier, work more effectively, reach people across more forms and stages of dementia, and ultimately stop or prevent disease rather than only slowing progression.

Clear Thoughts Foundation is not a licensed medical institution nor is intending to provide medical advice. Patients should speak with their healthcare provider to determine whether LEQEMBI or another treatment is appropriate for them.